IMMUNO-ONCOLOGY TARGETS TO IMPROVE T-CELL METABOLIC RESPONSE
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 28, 2023
app pub date -
Nov 18, 2021
filing date -
Nov 18, 2021
priority date (Note) -
Published
status (Latency Note)
Importance
Abstract
The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods utilizing Meteorin-like (METRNL), C-X-C Motif Chemokine Receptor 6 (CXCR6) and/or endogenous C-X-C Motif Ligand 16 (CXCL16) as immune-oncology targets. Accordingly, in one aspect, the present invention provides compositions and methods directed to the knockout of METRNL, CXCR6 and/or CXCL16 expression in a cell. In particular embodiments, the cell is a T cell. In a specific embodiment, the present invention provides an engineered T-cell comprising disruption in the METRNL, CXCR6 and/or CXCL16 gene sequence. In another embodiment, an engineered T-cell comprises (a) at least one chimeric antigen receptor (CAR); and (b) at least one genomic disruption of METRNL, CXCR6 and/or CXCL16. In certain embodiments, the genomic disruption is performed using a CRSIPR endonuclease system.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully